In Australia, for example, the recent Medicare coverage (government funding) approval for 177Lu-DOTATATE therapy included a provision for use in neuroendocrine tumors or other tumors with higher somatostatin expression (e.g., renal cell carcinoma, breast cancer, meningioma). The gene discussed is SST; the disease is hereditary clear cell renal cell carcinoma.